SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
Status:
Completed
Trial end date:
2019-02-15
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg
compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease
activity, fatigue, and predictability of disease flares in patients with axial
spondyloarthritis (axSpA) who had an inadequate response to prior non-steroidal
anti-inflammatory drugs (NSAIDs). This study also explored the efficacy and safety of
secukinumab 300 mg compared to secukinumab 150 mg from Week 8 to Week 24 in order to assess
the potential additional benefits of dose escalation in patients with axSpA.